

Facts: Multiple Myeloma Staging (Durie-Salmon system)
- Based on 4 factors: Hemoglobin, serum calcium, x-ray abnormality and amount of abnormal monoclonal immunoglobulin in blood or urine
- Stage I: slightly decreased Hb, normal serum Ca, normal x-ray or only one area of bone damage, relatively small monoclonal immunoglobulin
- Stage II: between I and III
- Stage III: Hb <> 12 mg/dL, three or more areas of bone damage, large amount of monoclonal immunoglobulin
Multiple Myeloma Imaging Staging
- Staging and monitoring is very important to management decision.
- Studies of the National Oncologic PET Registry with 1300 myeloma patients showed that 36.5% of the time, treating physicians changed the intended management on the basis of PET/CT results
- Traditional radiologic staging is to use skeletal survey but it can underestimate extent and magnitude of disease. Bone scan and gallium scan are unreliable.
- Whole-body MRI has been used but it can be difficult to differentiate active disease from scar tissue, necrosis, fracture or benign disease
- Several studies performed to assess the utility of FDG PET in staging and monitoring of multiple myeloma: they found that FDG PET is useful and superior to radiography in staging of newly diagnosed non-secretory myeloma (PET can upstage disease, can show bone/bone marrow abnormality in the absence of radiographic bone damage, can show sites of extramedullary disease), restaging and monitoring of non-secretory myeloma
- FDG PET also can help differentiating multiple myeloma from monoclonal gammopathy of uncertain significance (MGUS)
FDG-PET has recently been approved for reimbursement by the U.S. Medicare & Medicaid Services.
References:
1. Durie BGM, Waxman AD, D'Agnolo A, Williams CM. Whole-body 18-F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463
2. Dimopoulos M, Moulopoulos LA, Terpos E. A new pet for myeloma. Blood 2009;114:2007-2008.
3. The American Cancer Society. How is multiple myeloma staged? Link